Lifeward pivots to oral insulin with Oratech buy, $10M financing, as AlterG revenue drops 22%

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Acquired Oratech Pharmaceuticals and ORMD-0801 oral insulin technology, entering Phase 2 trial prep; $4.9M IPR&D charge hit Q1 earnings. Represents major diversification beyond medical devices into biotech drug development.

  MD&A: Oratech acquisition verify on EDGAR →
• high

  Closed $10M convertible note financing with Oramed (related party), creating $6.8M warrant liability and potential dilution; authorized shares increased 33% to 100M to accommodate conversions.

  MD&A: Oramed financing verify on EDGAR →
• high

  Revenue fell 22% to $3.9M as AlterG shipments dropped $1.3M due to working capital constraints impacting supply chain; gross margin compressed 800bps to 34.2% from lower volumes and tariffs.

  MD&A: Revenue and margins verify on EDGAR →